Join
Live feed
·
PRReleasevia Quantisnow
Cellectar Biosciences Inc. logo

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

ByQuantisnow·Wall Street's wire, on your screen.
CLRB· Cellectar Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLRB (Cellectar Biosciences Inc.) and more on Quantisnow.